HeartBeam Inc. (NASDAQ: BEAT) has announced the initiation of a pilot study for its investigational on-demand 12-lead ECG patch, designed to detect ischemia in patients with suspected coronary artery disease. The study, taking place at two hospitals in Belgrade, Serbia, will enroll approximately 50 patients and compare synthesized 12-lead ECG readings generated by the patch immediately after exercise stress testing against standard 12-lead ECGs. This trial supports HeartBeam’s regulatory strategy for a device that aims to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection, targeting the established approximately $2 billion patch-based monitoring market.
The company’s technology is the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable use, enabling physicians to identify cardiac health trends and acute conditions outside medical facilities. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology.
The pilot study’s results could be pivotal for HeartBeam’s ability to enter the ischemia detection market, a significant expansion from its current focus on arrhythmia. If successful, the patch could allow for earlier detection of coronary artery disease, potentially reducing the need for invasive procedures and enabling more timely interventions. For the broader industry, this innovation could shift the standard of care for ambulatory cardiac monitoring, providing a non-invasive tool for continuous ischemia monitoring outside clinical settings. Healthcare providers may gain a new method to monitor high-risk patients remotely, while patients could benefit from reduced hospital visits and improved quality of life.
HeartBeam’s technology is particularly relevant given the prevalence of coronary artery disease, a leading cause of death globally. The ability to detect ischemia on demand could improve outcomes for millions of patients. The company’s focus on synthesizing a 12-lead ECG from a compact patch addresses a key limitation of current ambulatory monitors, which primarily track heart rhythm and often miss transient ischemic events. By integrating ischemia detection, HeartBeam’s device could fill a critical gap in cardiac care.
Investors and industry observers will be watching the study closely, as positive results could accelerate regulatory submissions and market adoption. The company’s newsroom at https://ibn.fm/BEAT provides updates on its progress. For details on cleared indications for use, refer to https://www.heartbeam.com/indications.
